TWEAK and TNF regulation of sclerostin: A novel pathway for the regulation of bone remodelling

Advances in Experimental Medicine and Biology

Volumn 691, Issue , 2011, Pages 337-348

  Findlay, David M ^a   Atkins, Gerald J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Osteoblast; Sclerostin; TNF; TWEAK

Indexed keywords

DICKKOPF 1 PROTEIN; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; WNT PROTEIN; BONE MORPHOGENETIC PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

BONE DEVELOPMENT; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE DELETION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ARTICLE; BIOLOGICAL MODEL; CYTOLOGY; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING;

BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOGENESIS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTORS; WNT PROTEINS;

EID: 79954445382     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6612-4_34     Document Type: Conference Paper

References (38)

1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem;272(51):32401-32410
2. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, Dayer JM (2002) Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 4(2):126-133
3. Wiley SR, Winkles JA (2003) TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 14(3-4):241-249
4. Feng SLY, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, Peifley KA, Winkles JA (2000) The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156(4):1253-1261
5. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, Desplat-Jego S, Chicheportiche Y, Dietrich PY (2000) TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32(1):102-107
6. Yepes M, Brown SAN, Moore EG, Smith EP, Lawrence DA, Winkles JA (2005) A soluble fn14-fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia 1. Am J Pathol 166(2):511-520
7. Campbell S, Michaelson J, Burkly L, Putterman C (2004) The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 9:2273-2284
8. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA (1999) The mitogeninducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274(46):33166-33176
9. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA (2003) The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 371(Pt 2):395-403
10. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA (2003) TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 23(4):594-600
11. Ando T, Ichikawa J, Wako M, Hatsushika K, Watanabe Y, Sakuma M, Tasaka K, Ogawa H, Hamada Y, Yagita H, Nakao A (2006) TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther 8(5):R146
12. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y (2004) IL-6, RANKL, TNFalpha/ IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15(1):49-60
13. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Gortz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS (2003) Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48(7):2042-2051
14. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR (2004) Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: Expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 25(4):565-573
15. Crotti TN, Ahern MJ, Lange K, Weedon H, Coleman M, Roberts-Thomson PJ, Haynes DR, Smith MD (2003) Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: Quantification using color video image analysis. J Rheumatol 30(11):2319-2324
16. Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatni AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, Haynes DR (2006) The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27(30):5212-5219
17. Howie DW, Neale SD, Stamenkov R,McGee MA, Taylor DJ, Findlay DM (2007) Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am 89(8):1818-1825
18. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H (2006) TWEAK is a novel arthritogenic mediator. J Immunol 177(4):2610-2620
19. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K (2006) Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 177(9):6433-6439
20. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ (2009) Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)- dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24(8):1434-1449
21. Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, O'Loughlin P D, Morris HA (2007) Metabolism of vitamin D(3) in human osteoblasts: Evidence for autocrine and paracrine activities of 1alpha,25-dihydroxyvitamin D(3). Bone 40(6): 1517-1528
22. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171(1):131-137
23. Komori T (2006) Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99(5):1233-1239
24. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ (2005) The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280(21):20274-20285
25. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ (2003) Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63(17):5357-5362
26. Kim YJ, Kim HN, Park EK, Lee BH, Ryoo HM, Kim SY, Kim IS, Stein JL, Lian JB, Stein GS, van Wijnen AJ, Choi JY (2006) The bone-related Zn finger transcription factor Osterix promotes proliferation of mesenchymal cells. Gene 366(1):145-151
27. Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L (2005) TNFalpha and pathologic bone resorption. Keio J Med 54(3):127-131
28. Baron R, Rawadi G, Roman-Roman S (2006) Wnt signaling: A key regulator of bone mass. Curr Top Dev Biol 76:103-127
29. Ott SM (2005) Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 90(12):6741-6743
30. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24(9):1572-1585
31. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J 19(13):1842-1844
32. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860-869
33. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Lowik CW (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22(1):19-28
34. Atkins GJ,Welldon KJ, Halbout P, Findlay DM (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20(4):653-664
35. Barragan-Adjemian C, Nicolella D, Dusevich V, Dallas MR, Eick JD, Bonewald LF (2006) Mechanism by which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: Similarities with mineralization of lamellar bone. Calcif Tissue Int 79(5):340-353
36. Chan A, van Bezooijen RL, Lowik CW(2007) A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Curr Opin Investig Drugs 8(4):293-298
37. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, RichardsWG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156-163
38. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T (2003) TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem 278(34):32317-32323